Trial result ·
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This study looked at children with recessive dystrophic epidermolysis bullosa, or RDEB. RDEB is a rare skin disease passed down in families. The main trial gave cells from umbilical cord tissue, called UC-MSC. The cells were given as a drip into a vein. Each child got the cells in one period and a dummy drip in another. Neither the families nor the staff knew which came when. In this part of the trial, researchers spoke with 10 parents and 6 children. The talks took place about 3 and 12 months after the start.
What they found
Families said RDEB caused much pain and itch in daily life. With the cells, people reported less pain and itch. They also reported better wound healing and fewer dressing changes. This often meant more energy, better eating and more daily activity. These gains were stronger during the active treatment. The main downside was trouble getting into a vein. Of 13 people seen in both periods, 10 could tell which period was active. All parents said they would let their child have the treatment again.
What it means for patients
The authors say the talks show how families see the benefit of UC-MSC. They say the benefit seemed clearest in children with milder RDEB. They add that talks like these can show real life effects. Number scores in a trial may miss some of these effects.
Why it is not certain yet
These findings come from what families said, not from measured tests. The study spoke with only 10 parents and 6 children. The people were chosen on purpose, not at random. The abstract does not give the main trial's measured results.
Source
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial.
PubMed · PMID 42237200We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Epidermolysis bullosa publications